Published in Clin Pharmacol Ther on March 01, 1999
Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans. Acta Pharmacol Sin (2011) 0.81
A New Tool for in vivo Manipulation of Brain microRNA Levels: The Work of Smalheiser et al. (2014). Front Psychiatry (2015) 0.75
Possible drug-drug interaction in dogs and cats resulted from alteration in drug metabolism: A mini review. J Adv Res (2015) 0.75
Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother (1993) 1.79
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther (2009) 1.66
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J (2005) 1.53
Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother (1992) 1.45
Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol (2009) 1.41
Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. Eur J Clin Pharmacol (2013) 1.35
Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. Br J Anaesth (2000) 1.33
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother (2007) 1.33
Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother (1992) 1.25
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.24
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther (2008) 1.23
Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics (1999) 1.23
The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J (2007) 1.21
Pharmacokinetics of inhaled anaesthetics in a clinical setting: description of a novel method based on routine monitoring data. Br J Anaesth (2000) 1.20
Dosing accuracy of commonly used disposable insulin pens. Curr Med Res Opin (2010) 1.20
Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet (1995) 1.19
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis (1991) 1.15
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol (2007) 1.14
Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet (1998) 1.14
Lipophilicity at pH 7.4 and molecular size govern the entry of the free serum fraction of drugs into the cerebrospinal fluid in humans with uninflamed meninges. J Neurol Sci (1994) 1.14
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother (2008) 1.14
Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule. Br J Clin Pharmacol (1990) 1.08
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther (2010) 1.06
Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother (1998) 1.05
Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther (1995) 1.05
Effect of antacid medication on the pharmacokinetics of temafloxacin. Clin Pharmacokinet (1992) 1.05
Triamterene nephrolithiasis. JAMA (1980) 1.03
Lack of bioequivalence of a generic mefloquine tablet with the standard product. Eur J Clin Pharmacol (1998) 1.02
Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Clin Pharmacol Ther (1999) 1.01
Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg. J Urol (1993) 0.97
Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. Int J Clin Pharmacol Ther Toxicol (1989) 0.97
Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies. Antimicrob Agents Chemother (1996) 0.93
Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet (1992) 0.93
Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Antimicrob Agents Chemother (1998) 0.93
Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother (2001) 0.93
Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol (1993) 0.93
Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther (2010) 0.92
Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. Int J Antimicrob Agents (1998) 0.92
Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation. Int J Clin Pharmacol Ther (2005) 0.92
Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man. Eur J Clin Pharmacol (1993) 0.91
Dermal absorption of permethrin following topical administration. Eur J Clin Pharmacol (2005) 0.90
Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients. Antimicrob Agents Chemother (1997) 0.90
Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J Antimicrob Chemother (2007) 0.90
Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother (2013) 0.89
Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther (2000) 0.89
Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol (2000) 0.89
Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol (2011) 0.89
Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother (2010) 0.88
Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. Eur J Pharm Biopharm (2008) 0.88
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob Agents Chemother (2010) 0.88
Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin. Antimicrob Agents Chemother (1994) 0.88
Fatal complications after myelography with meglumine diatrizoate. Neuroradiology (1990) 0.88
Pharmacokinetics of temafloxacin in patients with liver impairment. Clin Pharmacokinet (1992) 0.88
Comparison of tissue concentrations after intramuscular and topical administration of ketoprofen. Pharm Res (2001) 0.87
Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos (2005) 0.87
Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose. Infection (1997) 0.87
Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther (2001) 0.87
Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob Agents Chemother (2001) 0.86
In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. J Antimicrob Chemother (1988) 0.86
Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther (1998) 0.86
Pharmacokinetics of triamterene and its metabolite in man. J Pharmacokinet Biopharm (1982) 0.86
Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther (1993) 0.86
Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. Curr Drug Metab (2010) 0.85
Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs (2008) 0.85
Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis. Antimicrob Agents Chemother (2009) 0.85
Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2. Eur J Clin Pharmacol (1992) 0.85
Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther (2007) 0.83
Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection (1991) 0.83
Pharmacodynamics and pharmacokinetics of furosemide combinations with potassium-retaining and thiazide-like diuretics: clearance and micropuncture studies. Naunyn Schmiedebergs Arch Pharmacol (1986) 0.83
Differential effects of EGF receptor signalling on neuroblast lineages along the dorsoventral axis of the Drosophila CNS. Development (1998) 0.82
Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Int J Clin Pharmacol Ther (2000) 0.82
The true composition of kidney stones passed during triamterene therapy. J Urol (1985) 0.81
Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur J Clin Pharmacol (1996) 0.81
Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. Infection (1993) 0.81
Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment? Eur J Clin Pharmacol (1988) 0.81
Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid. Antimicrob Agents Chemother (1993) 0.81
[Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy]. Med Monatsschr Pharm (2002) 0.81
Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues. Antimicrob Agents Chemother (1994) 0.80
Drug metabolism biosensors: electrochemical reactivities of cytochrome P450cam immobilised in synthetic vesicular systems. J Pharm Biomed Anal (1998) 0.80
Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother (2011) 0.80
Liver and gut mucosa acetylation of mesalazine in healthy volunteers. Int J Clin Pharmacol Ther (2000) 0.79
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol (2012) 0.79
[How well do gyrase inhibitors work? The pharmacokinetics of quinolones]. Pharm Unserer Zeit (2001) 0.79
Pharmacokinetics of pefloxacin in normal and impaired renal function. Arzneimittelforschung (1988) 0.79
The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther (2003) 0.79
In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. Infection (1986) 0.79
Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med (1989) 0.78
Absorption behavior of sulpiride described using Weibull functions. Int J Clin Pharmacol Ther (1995) 0.78
Improvement of pancreatic capillary blood flow does not augment the pancreatic tissue concentration of imipenem in acute experimental pancreatitis. Eur Surg Res (1996) 0.78